Pyxis Oncology (PYXS)

Overall impact
B (68)

Commentary

Pyxis Oncology is a strong overall performer. With a 'B' rating of 68.1 for overall impact (79th percentile compared to all companies), Pyxis Oncology ranks 323rd out of 645 industry peers, behind Curium Pharma, Allena Pharmaceuticals, Pluristem Therapeutics and 319 others, and ahead of Viking Therapeutics, Kadmon, Madrigal Pharmaceuticals and 319 others. On top material causes for Pyxis Oncology's industry (Biotechnology), Pyxis Oncology performs well in Technology Innovation (94.9 score), Child and Maternal Health (95.4), Accountable Institutions (88.3) and 11 other causes where it received an 'A' score and performs poorly in Improved Mental Health (27.7 score), Reduced Waste (35.0), Improved Mental Health (27.7) and 5 other causes where it received a 'D' or 'F' score.
Impact
Cause PYXS
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2018
Employees
54
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Massachusetts, United States
Share classes
PYXS
Description
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Material causes
Ethos considers the following causes material for Pyxis Oncology, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.